Global Blood Therapeutics is trading higher after the FDA expanded the approval for the company’s sickle cell disease therapy Oxbryta (voxelotor), allowing its use in children as young as four years of age. Oxbryta, discovered by Matthew Jacobson, chair of the Department of Pharmaceutical Chemistry at the University of California, San Francisco, was cleared under the FDA’s accelerated pathway for approval In Nov. 2019.
